Preclinical models have showed that inhibition of the PI3K/mTOR pathway decreases tumour activity and induced apoptosis when combined with oestrogen deprivation in ER+ tumour cells (Sanchez et al, 2011), providing a rationale for combining the two regimens in a clinical setting. The gene discussed is ESR1; the disease is neoplasm.